'Alarming' Spike in Liver Disease Deaths; Can PPIs Cause Lupus? IBS and Depression
(MedPage Today) -- U.S. deaths from liver disease increased at an "alarming rate" during the COVID-19 pandemic, data from the National Vital Statistic System revealed. (Journal of Hepatology)
Analyses of two pharmacovigilance databases confirmed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - August 19, 2022 Category: Gastroenterology Source Type: news
Organ Damage in Lupus: Some Ethnicities Bear More Burden Than Others
(MedPage Today) -- Rates of end-organ disease in systemic lupus erythematosus (SLE) differed significantly among races and ethnicities in a longitudinal California cohort, researchers found.
The burden on white patients was the lightest overall... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 16, 2022 Category: Rheumatology Source Type: news
New annotations in RefSeq
In June and July, the NCBI Eukaryotic Genome Annotation Pipeline released twenty-six new annotations in RefSeq for the following organisms: Anopheles coluzzii (mosquito) Anopheles funestus (African malaria mosquito) Astyanax mexicanus (Mexican tetra) Athalia rosae (coleseed sawfly) Bactrocera dorsalis (oriental fruit fly) Brassica napus (rape) Brienomyrus brachyistius (bony fish) Canis lupus dingo (dingo) (pictured) Caretta caretta (Loggerhead turtle) Dendroctonus ponderosae … Continue reading New annotations in RefSeq →
The post New annotations in RefSeq appeared first on NCBI Insights. (Source: NCBI Insights)
Source: NCBI Insights - August 8, 2022 Category: Databases & Libraries Authors: NCBI Staff Tags: What's New Comparative Genomics Resource (CGR) Datasets Eukaryotic genome annotation Genome Data Viewer (GDV) RefSeq Source Type: news
Glitazone Drug May Cut Lupus Heart Risk
(MedPage Today) -- A way to reduce cardiovascular (CV) risk in people with systemic lupus erythematosus (SLE) without interfering with immune mechanisms could be near at hand, results of a clinical trial suggested
In a study involving 80 SLE patients... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - August 4, 2022 Category: Rheumatology Source Type: news
What Are Causes of Childhood Interstital Lung Disease?
Discussion
Interstitial lung disease in children (chILD) is less understood than adult interstitial lung disease (ILD) and is rare. Prevalence is ~ 0.13 to 16.2 per 100,000 children under age 17 years. chILD is an general term for respiratory disorders that are heterogeneous, chronic and impair lung function. While some define diffuse parenchymal lung disease (DPLD) separately, the term ILD usually encompases DPLD. chILD has variable definitions and is “usually diagnosed if three of the following features are present:
1) respiratory symptoms (cough, rapid and/or difficult breathing, and exercise intolerance),
2) res...
Source: PediatricEducation.org - August 1, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Monthly News Roundup - July 2022
GSK’s Benlysta Is First Approved Treatment for Pediatric Lupus Nephritis
Benlysta (belimumab) is now approved for children 5 to 17 years of age who have lupus nephritis and are receiving standard therapy. Benlysta is not recommended in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2022 Category: Pharmaceuticals Source Type: news
New lupus treatments offer a better chance for remission
Yale Medicine experts explain the autoimmune disease and discuss new drugs that are allowing doctors to offer more patients a better chance of remission. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 29, 2022 Category: Universities & Medical Training Source Type: news
FDA Approves Belimumab for Children With Lupus Nephritis FDA Approves Belimumab for Children With Lupus Nephritis
Children with lupus-related kidney damage can now receive the B-cell reducing therapy that adults with lupus nephritis have been receiving for the past 2 years.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 28, 2022 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news
BDCA2-Targeting Antibody May Be Effective for Cutaneous Lupus
(MedPage Today) -- Treatment with an investigational drug targeting the blood dendritic cell antigen 2 (BDCA2) receptor reduced skin disease activity in patients with cutaneous lupus erythematosus, the phase II LILAC study showed.
In patients... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - July 28, 2022 Category: Dermatology Source Type: news
GSK Announces US FDA Approval of Benlysta (belimumab) for Pediatric Patients with Active Lupus Nephritis
Benlysta is now the first and only biologic approved for adults and children who have lupus or lupus nephritis
London UK 27 July 2022 -- GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 27, 2022 Category: Drugs & Pharmacology Source Type: news
First Drug OK'd for Lupus Nephritis in Kids
(MedPage Today) -- The FDA expanded the approval of belimumab (Benlysta) to include treatment of pediatric patients with active lupus nephritis, drugmaker GSK announced on Wednesday.
Already approved in adults with lupus nephritis, belimumab's... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - July 27, 2022 Category: Pediatrics Source Type: news
Science Saturday: Lupus rates increasing, communities of color especially vulnerable
New research led by Mayo Clinic shows that more people are being diagnosed with lupus than in the past, while risks of severity and death remain the same. The study is published in BMJ Annals of the Rheumatologic Diseases. Lupus is a chronic autoimmune disorder that causes inflammation and pain throughout the body. Most common in women (9 of 10 diagnosed cases); it attacks both joints and organs – including the skin. "In our study, we confirmed that in… (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - July 23, 2022 Category: Research Source Type: news
Multiple Sclerosis Patients on the Most Effective Ways Doctors Can Treat Their Condition
Because multiple sclerosis involves nerve damage that can occur throughout the body, including brain connections, symptoms can vary widely and be progressive. That makes each patient’s journey unique, and can prompt challenges on both sides of the exam table.
Here’s what eight patients with the disease wish doctors knew when it comes to helping them manage the condition more effectively.
Diagnosis should be its own appointment
Although Dr. Claire Warren—a 70-year-old Stonington, N.Y.–based physician—has plenty of experience treating patients with all kinds of ailments, it wasn’t until sh...
Source: TIME: Health - July 21, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease freelance healthscienceclimate Source Type: news
U.S. Should Expect More Lupus Cases as Racial-Ethnic Diversity Grows
(MedPage Today) -- Incidence rates for systemic lupus erythematosus (SLE) almost doubled in Olmsted County, Minnesota, from 1976 to 2018, according to a new study, with the investigators suggesting that the area's changing demographics "at least... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - July 18, 2022 Category: American Health Source Type: news
COVID Boosters Can Help People With Lupus
A new study shows people with lupus who get a COVID booster shot after full vaccination are half as likely to experience a COVID infection afterward. (Source: WebMD Health)
Source: WebMD Health - July 13, 2022 Category: Consumer Health News Source Type: news
